Arranta Bio Named Honoree in GrowFL Companies to Watch
Arranta Bio is pleased to be among the top 50 second-stage companies in Florida selected as honorees in the 2020 GrowFL Florida Companies to Watch, a statewide competition that identifies companies expected to see significant growth over the next several years. The 2020 GrowFL Florida Companies to Watch awards celebration is brought to you by […]
Selecting a Microbiome CDMO Partner for the Long Term, Arranta Bio Shares
As more microbiome-based therapies progress through the clinic toward approval for market launch, concerns over the lack of outsourcing capacity for process development and commercial manufacturing of live biotherapeutic products are increasing. Arranta Bio is investing heavily in both its process development and cGMP manufacturing capabilities for the supply of clinical trial material and in […]
Arranta Bio Announces Completion of Its Microbiome Process Development Laboratory Expansion and Commitment to Additional Early Clinical GMP Capacity
Arranta Bio, the leading microbiome contract development and manufacturing organization (CDMO), announced the completion of its process development laboratory expansion project and a commitment to add additional early-clinical GMP capacity at its Center of Excellence for Microbiome Process Development and Early Clinical Supply. Arranta has completed the expansion of purpose-built microbiome process development laboratories in […]
Oxidien Pharmaceuticals Announces Favorable Response from FDA on Proposed Development Plan
UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for secondary hyperoxaluria, announced that it has received encouraging responses from the U.S. Food and Drug Administration (FDA) regarding their proposed Phase 1/2 trial in secondary hyperoxaluria patients and other development plans for its lead drug candidate. […]
Arranta Bio Announces the Acquisition of Captozyme™, Creating a Center of Excellence for Microbiome Development and Clinical Supply
Arranta Bio, a contract development and manufacturing organization (CDMO), announced the acquisition of UF Innovate alumni startup Captozyme™, a leader in health care for and through the gut using novel enzymes and live biotherapeutics. With the acquisition, Arranta Bio will establish its Center of Excellence for process and analytical development and early clinical supply for […]
Captozyme Named to Gator100 List of Fastest Growing Companies
Captozyme Inc. was named among the top 50 fastest-growing UF alumni led businesses on the University of Florida’s annual 2019 Gator100. Captozyme is a graduate of both UF Innovate incubators. Sponsored by the UF Alumni Association and in partnership with the UF Entrepreneurship & Innovation Center, the Gator100 recognizes the 100 fastest-growing businesses owned or […]
Resource Rich: UF Innovate | The Hub Offers Even More After Doubling in Size (Business in Greater Gainesville)
In January, The Hub opened the doors to an expansion that doubled the building to 100,000 square feet. The mixed-use business incubator has served startup companies in biomedicine, agricultural technology, food sciences, information technology, and other areas since October 2011. The building — including both the old and new sections — is more than 75 […]
Captozyme Initiates Clinical Study of Nephure™ Oxalate-Reducing Enzyme (BusinessWire)
UF Innovate incubator graduate Captozyme, Inc. announced that it is initiating a prospective double-blind, randomized, placebo controlled, cross-over study, with Nephure™, an oxalate reducing enzyme, to determine the extent to which Nephure vs. placebo reduces urinary oxalate excretion (mg/24 hour) in healthy subjects who are provided a controlled diet. Captozyme is a graduate of both […]